TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06798376

Intervention type: DRUG
Intervention: ≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles

Intervention type: DRUG
Intervention: ≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed
Study: NCT06799169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
Study: NCT06454383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05218460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
Study: NCT05471622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge for PHPC Referral
Description: The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
Study: NCT06798012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-411
Description: TAK-411 IV infusion.
Study: NCT06799676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a combination treatment of Linperlisib and the VRD regimen
Description: Subjects will be administered Linperlisib orally at doses of 40 mg, 60 mg, or 80 mg once daily for 4 consecutive weeks, combined with the VRD regimen at standard doses. Subsequently, during the expansion phase, at least four cycles of Linperlisib at the recommended Phase II dose (RP2D) will be combined with the VRD regimen for induction therapy.
Study: NCT06798844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: SCS is an established treatment for chronic neuropathic pain and the implantation procedure in this study follows the conventional clinical approach. Under local anaesthesia, a lead electrode is positioned in the spinal epidural space at the Th8-Th10 vertebral levels. The electrode is then connected to an external stimulator (implantable pulse generator, IPG), used for the 3-week external trial stimulation. Upon completion of the core trial, the electrode may either be removed or connected to an internal IPG, after extensive counselling and dependent on the FOG outcome and patient's preference. A subsequent long-term open label phase will evaluate the long-term efficacy and safety of SCS on FOG, with a follow-up period of six months. Electrophysiological recordings of the dorsal spinal cord will be conducted at the end of the external trial stimulation and at the 6-month follow-up.

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal electrophysiological recordings
Description: The sole purpose of the control groups in this study, is to facilitate the interpretation of spinal cord electrophysiological characteristics in PD freezers by providing a comparison with individuals without the condition.

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal electrophysiological recordings
Description: The sole purpose of the control groups in this study, is to facilitate the interpretation of spinal cord electrophysiological characteristics in PD freezers by providing a comparison with individuals without the condition.
Study: NCT06799819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility group
Description: Free mobility between FDG injection and scanning (without exiting the Nuclear Medicine Department)
Study: NCT04452331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Access Audio
Description: Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Access, Patient and Provider Aware of Recording
Description: Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Access, Provider Unaware of Recording
Description: Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
Study: NCT06327074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaged Approach to Lung Cancer Screening
Description: Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart
Study: NCT06238895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tardyferon
Description: Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tardyferon
Description: Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
Study: NCT06798519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC364 Injectable Suspension
Description: Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline Tablets
Description: Subjects in rasagiline tablets cohort will receive 1 mg of rasagiline tablets orally once daily for 20 days, followed by 2 mg once daily for 5 days. Subjects will remain domiciled at the clinic stay until Day 26 and have a follow-up visit on Day 29 due to PK and PD blood sample collections
Study: NCT06798441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brush Only
Description: Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. Subjects will record their twice daily product usage on a subject diary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Rinse (Jolly Rancher Prototype)
Description: Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Rinse (LISTERINE® Total Care Zero Alcohol)
Description: Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
Study: NCT06357806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 100mg/10ml/1bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: 100mg/10ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2b
Description: 180ug/0.5ml/1bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFNα-2b
Description: 180ug/0.5ml/1bottle
Study: NCT05178524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIFICO
Description: Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
Study: NCT04878328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Onsite Point-of-care
Description: Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
Study: NCT06799455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: participants either receive the ETT during the procedure
Study: NCT06357806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs
Description: tablets
Study: NCT06798155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Music Listening Therapy
Description: Type of Intervention: Pre- and postoperative listening to standardized music sequences designed specifically for relaxation and pain management.~Delivery Method: Sessions are conducted via the Music Care® application, using a tablet and headphones provided during hospitalization. Participants select their preferred music style, tempo, and tracks to tailor the experience to their preferences.~Duration and Schedule:~Pre-surgery: One 20-minute session in a dedicated room before entering the operating theater.~Post-surgery: Daily 20-minute sessions at home for 28 days post-surgery using participants' own devices (smartphone, tablet, or computer).~Purpose: To evaluate the effect of music on reducing postoperative pain, minimizing analgesic use, and improving the quality of life.~Distinctiveness: This intervention uniquely integrates patient-controlled music preferences with a structured listening regimen before and after surgery, offering a personalized approach to enhancing recovery outcom
Study: NCT06799338

Intervention type: DRUG
Intervention: Lenacapavir Injection
Description: Patients will be included if they initiated LEN from 20 June 2023 to 30 June 2024.~All collected data are routinely reported by clinicians in medical records. All clinical decisions All collected data are routinely reported by clinicians in medical records, and will be collected using a dedicated electronic case report form (eCRF) created on this purpose, to ensure confidentiality of data.
Study: NCT06798324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation. Active tDCS involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Varenicline 1mg BID
Description: Varenicline is the most effective approved treatment for quitting smoking. Varenicline as per standard prescribing for dose escalation (i.e. Days 1 to 3: 0.5 mg once daily; Days 4 to 7: 0.5 mg twice daily; Days 8 to end of treatment: 1 mg twice daily) will be given concurrently over the same 2 weeks as the tDCS protocol and continue for an additional 10 weeks as per standard treatment duration recommended on the product monograph for a total of 12 weeks of varenicline treatment. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).~The target quit date for smoking cessation will be on the last day of the two weeks of daily tDCS which corresponds to the recommended quit date after starting varenicline treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline 1mg BID
Description: Varenicline is the most effective approved treatment for quitting smoking. Varenicline as per standard prescribing for dose escalation (i.e. Days 1 to 3: 0.5 mg once daily; Days 4 to 7: 0.5 mg twice daily; Days 8 to end of treatment: 1 mg twice daily) will be given concurrently over the same 2 weeks as the tDCS protocol and continue for an additional 10 weeks as per standard treatment duration recommended on the product monograph for a total of 12 weeks of varenicline treatment. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).~The target quit date for smoking cessation will be on the last day of the two weeks of daily tDCS which corresponds to the recommended quit date after starting varenicline treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham tDCS consists of 30s of 2 mA at the beginning and at the end of the 6 session (ramp up and down), then receiving 0 mA stimulation for the middle 19 min. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
Study: NCT06799936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD Jumpstart- Tips priming intervention
Description: The intervention includes 2 components:~1. Patient Priming: Patients will receive the Jumpstart CKD- Tips communication priming tool within 1 week before and on the day of a target clinic visit, which includes surveys on (i) Understanding of illness and possible treatment options, (ii) Readiness for treatment discussion and information preferences, (iii) Health priorities, goals, and preferences (iv) Preferred roles in decision-making. The Jumpstart CKD- Tips patient priming sheet includes (a) A summary of their survey responses that can be shared with their healthcare team, and (b) Tips on communication with clinician during upcoming visit.~2. Clinician Priming: Within 1 week before and on the day of the target clinic visit, clinicians will receive a Jumpstart CKD- Tips clinician priming sheet which contains (a) An abstracted version of the patients' survey responses and (b) Communication tips tailored to the patient's responses based on Vitaltalk curricula materials.
Study: NCT06799442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will be placed in lateral position with the surgical site upward. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. An echogenic needle needle will be inserted using an in-plane approach and craniocaudally direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will be placed in lateral position with the surgical site upward. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. An echogenic needle needle will be inserted using an in-plane approach and craniocaudally direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 50 mic dexmedetomidine which is diluted to 2ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 100 mic fentanylwhich is also diluted to 2 ml.
Study: NCT06797999

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antibody-drug conjugate (ADC)
Description: ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
Study: NCT06798870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable appliances
Description: removable appliances; clear aligner and removable inclined plane, for correcting anterior crossbite vin mixed dentition patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable appliances
Description: removable appliances; clear aligner and removable inclined plane, for correcting anterior crossbite vin mixed dentition patient
Study: NCT06799299

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT06798584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeoSol Original Iron Supplement Tablets
Description: 325 mg of ferrous sulfate containing 65 mg of elemental iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeoSol Original Iron Supplement Tablets
Description: 325 mg of ferrous sulfate containing 65 mg of elemental iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeoSol Original Iron Supplement Tablets
Description: 325 mg of ferrous sulfate containing 65 mg of elemental iron

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 21st Century Gelatin Capsules
Description: 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 21st Century Gelatin Capsules
Description: 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 21st Century Gelatin Capsules
Description: 600 mg
Study: NCT06799923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser electrode
Description: A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).
Study: NCT06798714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: standard CABG without performing pericardial fenestration intraoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
Study: NCT06357806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs
Description: tablets
Study: NCT06799403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-assisted online stress management
Description: Participants gain access to an online program comprised by 14 modules covering psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relapse. Participants are followed by a therapist providing feedback on exercises and progress. The program extends over approx. 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based face-to-face stress management
Description: The group-based format consists of 8 sessions of each 3 hours spread across 12 weeks. The sessions cover psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relaps. A group includes 8-9 participants
Study: NCT06798090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Band and Loop Space Maintainer Produced with Three-Dimensional Printer
Description: Band and loop space maintainer produced with three-dimensional printer using micro laser sinterisation method
Study: NCT04809051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival Metric
Description: Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival Metric
Description: Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SRTR Information Format
Description: The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SRTR Information Format
Description: The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
Study: NCT05238454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection